Novel natriuretic peptides: New compounds and new approaches

Mark W. Vogel, Horng H. Chen

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


The natriuretic peptides (NPs) are a group of structurally similar yet genetically distinct peptides that have diverse actions in cardiovascular, renal, and endocrine homeostasis. Since the discovery of atrial natriuretic peptide in 1981, the diagnostic, prognostic, and therapeutic significance of NPs have been studied extensively in relation to heart failure. Indeed, it now is understood that a hallmark of heart failure is the activation of the cardiac endocrine system, in particular the natriuretic peptide family including atrial natriuretic peptide and B-type natriuretic peptide. Currently, the only approved therapeutic application for NPs is the intravenous treatment of acute decompensated heart failure. However, in recent years there has been considerable research aimed at creating novel NPs and administering them via novel routes. This review focuses on the novel NPs that have been created and on novel approaches for their administration.

Original languageEnglish (US)
Pages (from-to)22-27
Number of pages6
JournalCurrent heart failure reports
Issue number1
StatePublished - Mar 2011


  • 3′,5′-Cyclic guanosine monophosphate
  • Hormone
  • Kidney
  • Markers
  • Ventricular dysfunction

ASJC Scopus subject areas

  • Emergency Medicine
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'Novel natriuretic peptides: New compounds and new approaches'. Together they form a unique fingerprint.

Cite this